-
Company Profile
Rhythm Pharmaceuticals Inc – Company Profile
Rhythm Pharmaceuticals Inc (Rhythm Pharmaceuticals) is a commercial-stage biopharmaceutical company. It develops therapies for the treatment of rare genetic diseases of obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin and kexin type 1 (PCSK1) and leptin receptor (LEPR) deficiency. The company’s lead drug IMCIVREE (setmelanotide), is a precision medicine to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. It is advancing RM-853, a ghrelin O-acyltransferase (GOAT) inhibitor targeting prader-willi syndrome. The company operates in the...
Add to Basket -
Product Insights
Cardiovascular Monitoring Devices Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Cardiovascular Monitoring Devices Pipeline Market Report Overview Cardiovascular monitoring and diagnostic devices are used to detect and feedback on abnormal episodes of the electrical functioning of the heart. The cardiovascular monitoring devices pipeline market research report provides comprehensive information about the cardiovascular monitoring devices pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Moreover, the report provides information about various pipeline products and their estimated...
-
Product Insights
Net Present Value Model: Corlanor
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Corlanor Drug Details Ivabradine hydrochloride (Procoralan/Corlentor,...
-
Product Insights
Net Present Value Model: Imcivree
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Imcivree Drug Details Setmelanotide (Imcivree) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BIIB-118
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry BIIB-118 Drug Details PF-05251749 was under development for the treatment of irregular sleep wake...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – setmelanotide hydrochloride ER
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry setmelanotide hydrochloride ER Drug Details Setmelanotide hydrochloride extended release formulation (CAM-4072) is under development for the...
-
Product Insights
Ventricular Tachycardia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ventricular tachycardia is a very fast heart rhythm that begins in the ventricles. Symptoms of ventricular tachycardia include dizziness, fainting, fatigue, chest pain, and shortness of breath. Causes include cardiomyopathy, ischemic heart disease, and heart failure. Risk factors include age, family history, and medical history. Treatment includes antiarrhythmic medication. The Ventricular Tachycardia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Ventricular Tachycardia, complete with analysis by stage of development, drug target, mechanism of action...
-
Product Insights
Melanocortin Receptor 4 (MC4R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocortin Receptor 4 – Drugs In Development, 2022, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Melanocortin Receptor 4 (MC4R) – Melanocortin 4 receptor (MC4R) is a G protein-coupled...